| |
|
Stage 1a |
Stage 2 |
Stage 3 |
Stage 4 |
Total |
| Codon 16 polymorphism |
Arg/Arg |
|
|
|
|
|
| Frequency |
4 |
3 |
5 |
2 |
14 |
| Percentb |
3.88% |
2.91% |
4.85% |
1.94% |
13.59% |
| |
|
|
|
|
|
| Arg/Gly |
|
|
|
|
|
| Frequency |
15 |
21 |
11 |
5 |
52 |
| Percent |
14.56% |
20.39% |
10.68% |
4.85% |
50.49% |
| |
|
|
|
|
|
| Gly/Gly |
|
|
|
|
|
| Frequency |
9 |
15 |
9 |
4 |
37 |
| Percent |
8.74% |
14.56% |
8.74% |
3.88% |
35.92% |
| |
|
|
|
|
|
| Total |
|
|
|
|
|
| Frequency |
28 |
39 |
25 |
11 |
103 |
| Percent |
27.18% |
37.86% |
24.27% |
10.68% |
100.00% |
| Codon 27 polymorphism |
Gln/Gln |
|
|
|
|
|
| Frequency |
8 |
13 |
9 |
3 |
33 |
| Percent |
7.77% |
12.62% |
8.74% |
2.91% |
32.04% |
| |
|
|
|
|
|
| Gln/Glu |
|
|
|
|
|
| Frequency |
15 |
20 |
13 |
5 |
53 |
| Percent |
14.56% |
19.42% |
12.62% |
4.85% |
51.46% |
| |
|
|
|
|
|
| Glu/Glu |
|
|
|
|
|
| Frequency |
5 |
6 |
3 |
3 |
17 |
| Percent |
4.85% |
5.83% |
2.91% |
2.91% |
16.50% |
| |
|
|
|
|
|
| Total |
|
|
|
|
|
| Frequency |
28 |
39 |
25 |
11 |
103 |
| Percent |
27.18% |
37.86% |
24.27% |
10.68% |
100.00% |
|
aStage 1-4 corresponds to GOLD COPD Stage I-IV
bDerived from frequency divided by total number of subjects (103). e.g., Arg/Arg Stage 1: 4/103=3.88% |
| Table 6: Distribution of codon 16 and codon 27 polymorphisms by COPD stage. |
